预约演示

更新于：2025-05-07

The HIV Netherlands Australia Thailand Research Collaboration

Thailand

更新于：2025-05-07

概览

关联

项与 The HIV Netherlands Australia Thailand Research Collaboration 相关的临床试验

NCT05930730

/ Recruiting临床2期IIT

A Phase 2, Non-inferiority, Open-label, Randomized Controlled Study to Evaluate the Immunogenicity and Safety of Comvigen (Bivalent) Vaccine as a Booster Dose in Adults Who Have Received a Previous Booster Dose of an Approved COVID-19 Vaccine

This study will assess the safety, reactogenicity and immunogenicity of a single dose of Comvigen (Bivalent, ChulaCov19 BNA159.2) vaccine or BIVALENT Pfizer/BNT vaccine as a booster among healthy males and non-pregnant females aged 18-64 years after receiving a previous booster dose of any approved mRNA COVID-19 vaccine for more than 3 months. The results of Combiven will be compared to BIVALENT Pfizer/BNT vaccine.

开始日期2023-10-09

申办/合作机构

University of Chulalongkorn

[+1]

NCT05350865

/ RecruitingN/AIIT

Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024

There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment

开始日期2023-01-30

申办/合作机构

The HIV Netherlands Australia Thailand Research Collaboration

[+5]

NCT04552015

/ TerminatedN/AIIT

Pilot Study for Development of Microneedles for Diagnosis of Latent Tuberculosis Infection

This study will evaluate new technique, microneedle, to detect latent tuberculosis (TB) in healthy volunteers

开始日期2021-04-08

申办/合作机构

The HIV Netherlands Australia Thailand Research Collaboration

100 项与 The HIV Netherlands Australia Thailand Research Collaboration 相关的临床结果

登录后查看更多信息

0 项与 The HIV Netherlands Australia Thailand Research Collaboration 相关的专利（医药）

登录后查看更多信息

190

项与 The HIV Netherlands Australia Thailand Research Collaboration 相关的文献（医药）

2025-03-15·AIDS

SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

Article

作者: Sokhela, Simiso ; Avihingsanon, Anchalee ; Kumarasamy, Nagalingeswaran ; Jacoby, Simone ; Tovar-Sanchez, Tamara ; Petoumenos, Kathy ; Eriobu, Nnakelu ; Delaporte, Eric ; Ayouba, Ahidjo ; Arriaga, Maria ; Woods, Joana ; Matthews, Gail V. ; Losso, Marcelo H. ; Mpoudi-Etame, Mireille ; Calmy, Alexandra ; Venter, W.D. Francois ; Grinsztejng, Beatriz ; Kouanfack, Charles ; Khoo, Saye ; Polizzotto, Mark N. ; Kaplan, Richard ; Borok, Margaret ; Papot, Emmanuelle ; Thaurignac, Guillaume ; Azwa, Iskandar

Objective:Data on the impact of coronavirus disease 2019 (COVID-19) in people with HIV (PWH) are lacking in resource-constrained settings. We utilized existing randomized clinical trials (RCTs) on antiretroviral therapies (ART) in HIV-1 infection to conduct a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey, between January and March 2021, while characterizing participants’ features.Design:Cross-sectional serosurvey.Methods:Demographic characteristics, medical history and a serum sample were collected from consenting PWH. Samples were analyzed centrally for immunoglobulin G antibodies to recombinant nucleocapsid and spike proteins derived from SARS-CoV-2 using a Luminex based assay.Results:The 549 participants recruited in 9 sites across Africa had a median age of 40 years (interquartile range, IQR [34–45]); 63.0% (346) were female. All were on ART; 81.8% (449) had an HIV-1 viral load <50 copies/ml, with CD4+ cell count median at 478/mm3 (IQR [320–677]). None had received vaccination against SARS-CoV-2. Forty participants (7.3%) had a prior SARS-CoV-2 PCR testing, of whom 10 were positive (1.8%). Crude SARS-CoV-2 seroprevalence was 36.2% (95% confidence interval (CI) [32.2–40.4]). In the explorative multivariable analysis, comparison of the characteristics of PWH with a positive SARS-CoV-2 serology with those with a negative or indeterminate serology: PWH with a body mass index (BMI) ≥30 kg/m2 were more likely to have a positive serology than those with a BMI <25 (adjusted odds ratio (aOR) = 2.39 [1.48–3.86], P < 0.001); and PWH living in Cameroon were less likely to have a positive serology.Conclusion:This study demonstrates a substantial seroprevalence level of SARS-CoV-2 in PWH in the first quarter of 2021, with a marked disparity with the number of COVID-19 PCR tests reported positive.

2025-02-05·Clinical Infectious Diseases

Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study

Article

作者: Borok, Margaret ; Dao, Sounkalo ; Eriobu, Nnakelu ; Kumarasamy, Nagalingeswaran ; Matthews, Gail V ; Dharan, Nila J ; Avihingsanon, Anchalee ; Petoumenos, Kathy ; Cisse, Mohamed ; Azwa, Iskandar ; Nyein, Phyo Pyae ; Hanson, Josh

AbstractIn this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant after controlling for confounding factors, including weight gain.

2025-01-01·Pediatric Pulmonology

Respiratory sequelae after COVID‐19 infection in Thai healthy children

Article

作者: Niyomkarn, Watit ; Deerojanawong, Jitladda ; Harnruthakorn, Chanthana ; Sophonphan, Jiratchaya ; Prapphal, Nuanchan ; Sritippayawan, Suchada ; Boonjindasup, Wicharn ; Niamsanit, Sirapoom

AbstractBackground and AimsThe long‐term respiratory sequelae of COVID‐19 infection in children remain poorly understood and may differ across countries. This study aims to investigate the respiratory sequelae, including residual respiratory symptoms and pulmonary function in Thai children. The secondary aim is to identify factors associated with the respiratory sequelae.Materials and MethodsThis is an observational study involving 56 healthy children, aged between 7 and 18 years, who were diagnosed with COVID‐19 infection from July 2021 to February 2023. Clinical data relating to COVID‐19 infection and persistent symptoms after the infection were assessed after the infection up to 6 months. Spirometry was performed to assess pulmonary function.ResultsPost‐COVID‐19 symptoms were identified in 14 patients (25%), with fatigue, cough, and dyspnea being common symptoms (28%–35%). A significant correlation was found between post COVID‐19 symptoms and pneumonia (OR = 6.00, 95%CI [1.54,23.33], p = .01). Abnormal pulmonary function was identified in 10 patients (17.8%) with obstructive impairment being the most common. However, there was no significant association between clinical factors and pulmonary function impairment.ConclusionProlonged respiratory symptoms and abnormal pulmonary function following COVID‐19 infection are not uncommon in children. The post‐COVID‐19 symptoms are possibly associated with COVID‐19 pneumonia.

100 项与 The HIV Netherlands Australia Thailand Research Collaboration 相关的药物交易

登录后查看更多信息

100 项与 The HIV Netherlands Australia Thailand Research Collaboration 相关的转化医学

登录后查看更多信息